Publication | Closed Access

The PPARγ agonist rosiglitazone prevents neuronal loss and attenuates development of spontaneous recurrent seizures through BDNF/TrkB signaling following pilocarpine-induced status epilepticus

Molecular PharmacologyPilocarpine-induced Status EpilepticusSpontaneous Recurrent SeizuresNeurophysiologyMedicineNeurotransmitterNeuropharmacologyNeuroprotectionNeurotransmissionNeurologyNeurosciencePharmacotherapyNeurochemistryPharmacologySynaptic SignalingPparγ Agonist RosiglitazoneMolecular NeurobiologySocial Sciences